Table 3.
Outcomes per treatment regimen
| Treatment regimen | LMB | BFM | HOVON | CODOX-M/IVAC | All | P value |
|---|---|---|---|---|---|---|
| N | 36 | 19 | 29 | 21 | 105 | |
| Response rates | ||||||
| Complete response | 22 (65%) | 10 (53%) | 20 (69%) | 15 (75%) | 67 (66%) | 0.501 |
| Partial response | 5 (15%) | 4 (21%) | 3 (10%) | 2 (10%) | 14 (14%) | 0.705 |
| Refractory disease | 7 (21%) | 5 (26%) | 6 (21%) | 3 (15%) | 21 (21%) | 0.858 |
| Not evaluable | 2 (6%) | 0 | 0 | 1 (5%) | 3 (3%) | |
| Relapse rates | ||||||
| Relapse (at 1 year after end of treatment, corrected for competing events) | 7% (95% CI 0–17%) | 0% (95% CI 0–0%) | 9% (95% CI 0–21%) | 12% (95% CI 0–28%) | 7% (95% CI 2–13%) | 0.612 |
| 5-year survival rates | ||||||
| Progression-free survival | 67% (95% CI 53–80%) | 74% (95% CI 57–91%) | 68% (95% CI 53–83%) | 71% (95% CI 54–88%) | 69% (95% CI 60–78%) | 0.966 |
| Overall survival | 66% (95% CI 53–80%) | 74% (95% CI 54–93%) | 71% (95% CI 54–88%) | 70% (95% CI 50–90%) | 69% (95% CI 60–78%) | 0.981 |